<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dewi Rochmawati</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author><author><style face="normal" font="default" size="100%">Yessy Puspitasari</style></author><author><style face="normal" font="default" size="100%">Tutik Kusmiati</style></author><author><style face="normal" font="default" size="100%">Atika</style></author><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Concordance of Sputum and Feces Samples for Detecting Mycobacterium Tuberculosis using Xpert® MTB/RIF Ultra</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Feces AFB test</style></keyword><keyword><style  face="normal" font="default" size="100%">Feces Xpert® MTB/RIF Ultra test</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis (MTB)</style></keyword><keyword><style  face="normal" font="default" size="100%">rifampicin resistance test</style></keyword><keyword><style  face="normal" font="default" size="100%">Xpert® MTB/RIF Ultra</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">167-173</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Tuberculosis (TB) remains a disease with high morbidity and mortality worldwide, and Indonesia ranks among the countries with the highest TB prevalence. There is a need to develop improved detection tools and explore alternative sample sources beyond sputum. Feces samples are one such nonsputum alternative. Xpert® MTB/RIF Ultra is a novel diagnostic tool used in Indonesia. This study aims to assess the concordance of both sputum and feces samples in detecting Mycobacterium tuberculosis (MTB) using Xpert® MTB/RIF Ultra. &lt;strong&gt;Methods: &lt;/strong&gt;An analytical observational study with a cross-sectional design was conducted on TB subjects at Dr. Soetomo Regional Public Hospital (RSUD Dr. Soetomo), Surabaya, and several community health centers (puskesmas) in Surabaya. Sputum and feces samples were collected from the same subjects. These subjects underwent Feces acid-fast bacilli (AFB) tests, sputum and Feces Xpert® MTB/RIF Ultra tests, and sputum culture tests (considered the gold standard), as well as rifampicin resistance tests for positive cultures. Sensitivity and positive predictive value (PPV) tests were conducted using Medcalc software, and the concordance test employed the Kappa value. &lt;strong&gt;Results:&lt;/strong&gt; The study involved 71 research subjects. The sensitivity of Feces AFB tests, sputum, and Feces Xpert® MTB/RIF Ultra tests was 7.3%, 97.6%, and 97.6%, respectively. The Cohen's Kappa consistency test for Feces AFB tests and sputum culture produced a Kappa value of 0.063 (p &amp;gt; 0.05). The Cohen's Kappa consistency test on sputum and Feces Xpert® MTB/RIF Ultra tests yielded a Kappa value of 0.409 (p &amp;lt; 0.05). The Cohen's Kappa consistency test on sputum and Feces Xpert® MTB/RIF Ultra tests compared with the rifampicin resistance tests resulted in Kappa values of 0.902 and 0.951 (p &amp;lt; 0.05). The CT value of Feces Xpert® MTB/RIF Ultra tests was higher than that of sputum Xpert® MTB/RIF Ultra tests. &lt;strong&gt;Conclusion:&lt;/strong&gt; A concordance exists between the results of sputum and Feces Xpert® MTB/RIF Ultra tests, but no concordance is observed between the results of Feces AFB tests and sputum culture tests. The higher CT value of Feces Xpert® MTB/RIF Ultra tests compared to sputum Xpert® MTB/RIF Ultra tests indicates a lower bacterial load in feces. Feces can be considered a viable alternative sample to sputum for MTB detection using Xpert® MTB/RIF Ultra.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">167</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Dewi Rochmawati&lt;sup&gt;1&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;1,2,3&lt;/sup&gt;, Yessy Puspitasari&lt;sup&gt;1&lt;/sup&gt;, Tutik Kusmiati&lt;sup&gt;4&lt;/sup&gt;, Atika&lt;sup&gt;5&lt;/sup&gt;, Hartono Kahar&lt;sup&gt;1,3&lt;/sup&gt;,*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Institute of Tropical Diseases, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Postgraduate School of Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Public Health Sciences Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author><author><style face="normal" font="default" size="100%">Sari Prabandari Prasetyaningrum</style></author><author><style face="normal" font="default" size="100%">Munawaroh Fitriah</style></author><author><style face="normal" font="default" size="100%">Aryati</style></author><author><style face="normal" font="default" size="100%">Jusak Nugraha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analysis of Covid-19 Neutralizing Antibody Levels Post Vaccination using Ichroma™ and iFlash Covid-19 Nab</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Ichroma</style></keyword><keyword><style  face="normal" font="default" size="100%">iFlash.</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutralizing Antibody</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">171-174</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; One of the efforts to control SARS-CoV-2 infection in health workers is vaccination. In this study, the levels of SARS-CoV-2 neutralizing antibody (nAb) in health workers were measured with Ichroma and iFlash. &lt;strong&gt;Methods:&lt;/strong&gt; This study applied an observational analytic design with a prospective cohort and was conducted at Dr. Soetomo Regional Public Hospital, Surabaya, from January to November 2021. The population of this study included a total of 75 health workers after taking the second dose of the SARS-CoV-2 (Sinovac) vaccine. The Covid-19 NAb levels of the population were tested with Ichroma and iFlash on day 0 before vaccination, as well as days 14 and 28, and months 3 and 6 after vaccination. &lt;strong&gt;Results: &lt;/strong&gt;The Friedman test indicated a significant difference in NAb levels according to the iFlash test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p &amp;lt; 0.05). The Wilcoxon test revealed a significant difference in NAb levels on day 14, day 28, month 3, and month 6. The results of the Cochran test showed a significant difference in the positivity of NAb according to the Ichroma test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p &amp;lt; 0.05). McNemar's test demonstrated that the COI at month 3 was not significantly different from that before vaccination; The COI at month 6 was not significantly different from those at days 14 and 28. The results of the Pearson correlation test and Bland–Altman plot indicated a moderate correlation between Ichroma and iFlash (r = 0.592, p = 0.002).&lt;strong&gt; Conclusion:&lt;/strong&gt; Neutralizing antibodies for Covid-19 were formed after day 14 and started to increase on day 28 and started to decrease in months 3 and 6. The levels of NAb for Covid-19 were measured with Ichroma and iFlash in roughly the same pattern and had a moderate positive correlation.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">171</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Hartono Kahar&lt;sup&gt;1,*&lt;/sup&gt;, Sari Prabandari Prasetyaningrum&lt;sup&gt;2&lt;/sup&gt;, Munawaroh Fitriah&lt;sup&gt;2&lt;/sup&gt;, Aryati&lt;sup&gt;2&lt;/sup&gt;, Jusak Nugraha&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Laboratory Instalation, Dr. Soetomo Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Clinical Pathology Specialization Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muhamad Robiul Fuadi</style></author><author><style face="normal" font="default" size="100%">Jusak Nugraha</style></author><author><style face="normal" font="default" size="100%">I Gde Rurus Suryawan</style></author><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author><author><style face="normal" font="default" size="100%">Aryati</style></author><author><style face="normal" font="default" size="100%">Gwenny Ichsan Prabowo</style></author><author><style face="normal" font="default" size="100%">Budi Utomo</style></author><author><style face="normal" font="default" size="100%">Reny I’tishom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Correlation of Apo E Gene Polymorphism with Recurrent Acute Coronary Syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute Coronary Syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">ApoE gene</style></keyword><keyword><style  face="normal" font="default" size="100%">PCR RFLP</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Public Health</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">450-453</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Recurrent cardiovascular disease (CVD) incidence puts patients at higher risk for mortality and morbidity. One of the CVD symptoms is acute coronary syndrome (ACS). Many genetic polymorphisms are CVD risk factors. This study’s purpose was to investigate the correlation between recurrent ACS incidence and apolipoprotein E (ApoE) gene polymorphism.&lt;strong&gt; Method&lt;/strong&gt;: Case-control design was used in this study. About 90 patients who visited the cardiology and internal medicine clinics at UNAIR Hospital in Surabaya, Indonesia, served as the study's subjects. There were 30 patients with recurrent ACS, 30 patients with a single ACS, and 30 patients with no history of cardiovascular disease. Afterward, using the polymerase chain reaction-restriction fragment length method, the ApoE gene polymorphism examination was carried out. The Tropical Disease Center UNAIR Laboratory conducted all laboratory testing. R&lt;strong&gt;esults&lt;/strong&gt;: In the recurrent ACS group, ApoE polymorphism genotype patterns were 5 subjects for ε2ε2 (16.67%), 23 subjects for ε3ε3 (76.66%), and 2 subjects for ε4ε4 (6.67%). Meanwhile, in the single ACS group, ApoE polymorphism genotype patterns were 6 subjects for ε2ε2 (20%), 22 subjects for ε3ε3 (73.4%), 1 subject for ε4ε4 (3.33%), and 1 subject for ε2ε3 (3.33%). And, in the non- ACS group, ApoE polymorphism genotype patterns were4 subjects for ε2ε2 (13.34%), 25 subjects for ε3ε3 (83.33%), and1 subject for ε4ε4 (3.33%). There was no correlation of ApoE gene polymorphism with recurrent ACS incidence by Chi-square analysis (p &amp;gt; 0.05). &lt;strong&gt;Conclusion&lt;/strong&gt;: ApoE gene polymorphism cannot significantly affect recurrent ACS incidence.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">450</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Muhamad Robiul Fuadi&lt;sup&gt;1&lt;/sup&gt;, Jusak Nugraha&lt;sup&gt;2,*&lt;/sup&gt;, I Gde Rurus Suryawan&lt;sup&gt;3&lt;/sup&gt;, Hartono Kahar&lt;sup&gt;2&lt;/sup&gt;, Aryati&lt;sup&gt;2&lt;/sup&gt;, Gwenny Ichsan Prabowo&lt;sup&gt;4&lt;/sup&gt;, Budi Utomo&lt;sup&gt;5&lt;/sup&gt;, Reny I’tishom&lt;sup&gt;6&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Public Health and Preventive Medicine Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Medical Biology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nur Fitri Hayati Melida Ritonga</style></author><author><style face="normal" font="default" size="100%">Ferdy R. Marpaung</style></author><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author><author><style face="normal" font="default" size="100%">Nunuk Mardiana</style></author><author><style face="normal" font="default" size="100%">Yessy Puspitasari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Performance Comparison of Urine Sediment Analytical Tool by  Flowcytometry and Digital Imaging with Standardized Manual  Microscopic Testing</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Digital imaging</style></keyword><keyword><style  face="normal" font="default" size="100%">Flowcytometry</style></keyword><keyword><style  face="normal" font="default" size="100%">Microscopic</style></keyword><keyword><style  face="normal" font="default" size="100%">Urine sediment</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">1189-1196</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Urine sediment examination provides numerous information about patient's kidney condition. Flowcytometry and digital imaging system could conduct automatic urine sediment analysis. Therefore, determining the diagnostic performance of the examination is very important in the management carried out by the clinician. This study aims to determine the diagnostic performance of urine flowcytometry and digital imaging sediment examination tools compared to manual microscopes that are standardized as gold standards. &lt;strong&gt;Methods: &lt;/strong&gt;This study is an analytical observational study with a cross-sectional approach on 92 urine samples of patients who attended the Internal Medicine Nephrology Polyclinic of Dr. Soetomo Academic Hospital Surabaya. The performance of flowcytometry and digital imaging methods is assessed by calculating sensitivity and specificity. Analysis of the suitability of each urine sediment parameter used Cohen's kappa. Urine sediment analysis with a light microscope was conducted with the Shih-Yung method as a gold standard. &lt;strong&gt;Results: &lt;/strong&gt;The erythrocyte parameters revealed a very favorable result with the concordance of the flowcytometry with the Shih-Yung method (κ=0.82) and fair results for WBC (κ=0.25), Epithelium (κ=0.57) and Cast (κ=0.27). At the same time, yeast had substantial conformity (κ=0.63). The digital imaging method showed substantive fit for WBC (κ=0.676), RBC (κ=0.621), fair for SEC (κ=0.42) and NSE (κ=0.24), moderate for Yeast (κ=0.45), and slight for Hyaline Cast (κ=0.074) and Path Cast (κ= 0.134) &lt;strong&gt;Conclusion: &lt;/strong&gt;The urine flowcytometry demonstrates better performance compatibility with a standardized manual microscope compared to urine digital imaging. However, pathological samples should still be verified with a manual microscope&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1189</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Nur Fitri Hayati Melida Ritonga&lt;sup&gt;1&lt;/sup&gt; , Ferdy R. Marpaung&lt;sup&gt;1&lt;/sup&gt; , Hartono Kahar&lt;sup&gt;1 &lt;/sup&gt;, Nunuk Mardiana&lt;sup&gt;2&lt;/sup&gt; , Yessy Puspitasari&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Clinical Pathology Dr Soetomo Academic Hospital/Faculty of Medicine Universitas Airlangga Surabaya, INDONESIA. &lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine Dr Soetomo Academic Hospital/Faculty of Medicine Universitas Airlangga Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>